SpringWorks Therapeutics, Inc. Common Stock (SWTX) is a publicly traded Healthcare sector company. As of May 20, 2026, SWTX trades at $46.99 with a market cap of $3.48B and a P/E ratio of -13.78. SWTX moved +0.00% today. Year to date, SWTX is +29.45%; over the trailing twelve months it is +25.21%. Its 52-week range spans $28.21 to $62.00. Analyst consensus is buy with an average price target of $47.00. Rallies surfaces SWTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
SpringWorks Secures Positive CHMP Opinion for First EU NF1-PN Therapy, Decision Q3 2025: SpringWorks Therapeutics received a positive CHMP opinion for conditional marketing authorization of mirdametinib to treat symptomatic, inoperable plexiform neurofibromas in adult and pediatric NF1 patients. European Commission decision expected in Q3 2025, positioning mirdametinib as potentially first and only EU therapy for NF1-PN.
| Metric | Value |
|---|---|
| Price | $46.99 |
| Market Cap | $3.48B |
| P/E Ratio | -13.78 |
| EPS | $-3.41 |
| Dividend Yield | 0.00% |
| 52-Week High | $62.00 |
| 52-Week Low | $28.21 |
| Volume | 5.01M |
| Avg Volume | 0 |
| Revenue (TTM) | $219.67M |
| Net Income | $-253.93M |
| Gross Margin | 93.23% |
11 analysts cover SWTX: 0 strong buy, 7 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $47.00.